# Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

> **NCT03029585** · PHASE2 · TERMINATED · sponsor: **NanOlogy, LLC** · enrollment: 10 (actual)

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **DRUG:** NanoPac® 100 mg/m2
- **DRUG:** NanoPac® 200 mg/m2
- **DRUG:** NanoPac® 300 mg/m2
- **DRUG:** NanoPac® 400 mg/m2
- **DRUG:** Standard of Care Intravenous Chemotherapy

## Key facts

- **NCT ID:** NCT03029585
- **Lead sponsor:** NanOlogy, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-19
- **Primary completion:** 2019-11-04
- **Final completion:** 2019-11-04
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029585, "Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03029585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*